OBESITY has steadily emerged as a significant public health concern in the Philippines with increasing prevalence over the past decades. It used to be a concern among the high-income group but it has ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

The Coalition for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, ...

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991. View on euronews ...

Shares of Novo Nordisk (NYSE: NVO) fell 3% today following the announcement that CEO Lars Fruergaard Jørgensen will step down from his role. The company stated t ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and ...

U.S.-listed shares of Novo Nordisk (NVO) are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook. The maker of blockbuster weight-loss ...

After an explosive debut on the New York Stock Exchange, Newsmax CEO Chris Ruddy joined Euronews’ business editor Angela Barnes on The Big Question to discuss the secret to the group’s success. View ...

Credit: Novo Nordisk. Self-paying patients will now be able to access NovoCare Pharmacy directly through the telehealth platform. The Company is working with Hims & Hers Health, Inc, LifeMD ...

Novo Nordisk announced its decision to partner with digital health providers to streamline access to Wegovy after a U.S. shortage has eased. And Novo will offer direct-to-consumer access via its ...

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Analyst downgrades Novo Nordisk, cuts price target to $64. The analyst highlights that Lilly's drugs, Mounjaro and Zepbound, will gain U.S. market share from Novo Nordisk's Ozempic and Wegovy.